Regular savings accounts offer attractive rates for disciplined savers, but come with strict rules on monthly deposits and withdrawals. Our guide breaks down the latest deals and what you need to know before committing your cash.
Chinese courts have executed four senior members of a Myanmar-based criminal organization for murder, trafficking, and running a multi-billion dollar scam operation that exploited thousands, including Chinese citizens. The move is part of a broader crackdown on cross-border cyber fraud hubs.
After months of political gridlock and a series of no-confidence votes, France's parliament is poised to adopt the contentious 2026 budget. The survival of Prime Minister Sebastien Lecornu's government hinges on Monday's vote, marking a critical juncture for the nation's fiscal and political stability.
Barclays initiates coverage of 4D Molecular Therapeutics with an Overweight rating and a $33 price target, citing a favorable industry backdrop with potential M&A tailwinds and shifting focus away from drug pricing pressures. The gene therapy developer also outlined key clinical milestones expected through 2026.
While Legend Biotech's CAR-T therapy Carvykti missed Q4 sales estimates, prompting mixed analyst reactions, some firms emphasize its curative potential and view the stock's recent decline as a strategic entry point for investors.
Ardelyx, Inc. (NASDAQ: ARDX) has received significant analyst upgrades, with TD Cowen and Jefferies raising price targets ahead of the company's fourth-quarter results. The optimism centers on the commercial trajectory of its flagship drug, tenapanor, for gastrointestinal and kidney conditions.
Clear Street downgrades Janux Therapeutics (JANX) to Hold, slashing its price target amid concerns over a lack of durability data for its lead candidate JANX007 and rising competitive pressures, despite a recent major collaboration deal with Bristol Myers Squibb.
Twist Bioscience kicks off fiscal 2026 with robust growth, reporting a 17% year-over-year revenue increase to $103.7 million. The company credits its semiconductor-based DNA synthesis platform and surging demand from AI-enabled drug discovery programs as key drivers, while reiterating its path to adjusted EBITDA breakeven within the year.
Fueled by new funding and AI-powered tools, the Internal Revenue Service is intensifying its scrutiny of gig economy and freelance income, making even small earnings reportable. Here’s what you need to know to stay compliant.
For those on a fixed income, inflation isn't just an economic indicator—it's a direct assault on financial security. Experts warn that failing to plan for rising costs can halve a retiree's purchasing power over decades. Here’s a strategic guide to building a resilient portfolio.
GIGABYTE is expanding its strategic partnership with AMD to launch a new generation of AI-enhanced gaming laptops, motherboards, and monitors. This collaboration integrates AMD's Ryzen AI and 3D V-Cache technologies directly into consumer hardware, aiming to deliver tangible benefits in gaming smoothness, system stability, and creative workflow acceleration.
While stocks priced between $10 and $50 can appear to offer an attractive balance of accessibility and maturity, their low price tags can sometimes mask underlying vulnerabilities. We examine three such companies where caution may be prudent.
Amidst market volatility and economic crosscurrents, income-focused investors are revisiting dividend stocks for potential stability and yield. We examine three Japanese companies offering yields from 3.3% to 6.3%, analyzing their sustainability and strategic outlook.
Aerospace systems provider Astronics Corporation launches its new automated circuit card testing system, designed to accelerate troubleshooting and maintenance for critical aviation and defense electronics, as analysts raise price targets on sustained sector demand.
Erasca (ERAS) gains significant analyst momentum as Mizuho initiates coverage with an 'Outperform' rating and a $16 price target, citing confidence in its 2026 proof-of-concept milestones for RAS-targeted cancer therapies.
ABIVAX (NASDAQ:ABVX) shares have skyrocketed over 2000% in recent months, fueled by speculation of an Eli Lilly buyout and promising clinical data for its lead drug. CEO Marc De Garidel has publicly dismissed the acquisition rumors as 'noise,' redirecting focus to the company's financing needs and advancing therapeutic programs.
Alibaba Group has pledged 3 billion yuan ($431 million) to promote its Qwen AI app during the upcoming Lunar New Year holiday, significantly outpacing similar campaigns by rivals Tencent and Baidu and marking a major escalation in China's competitive AI landscape.
Yamaha Motor's shares have delivered impressive multi-year returns, but a deep dive into valuation metrics suggests the current price may be running ahead of fundamentals. Analysis points to a significant premium based on cash flow and earnings multiples, raising questions about its near-term trajectory.
GitLab's strategic pivot to become an AI-centric development platform is facing heightened scrutiny from Wall Street. Recent analyst downgrades, citing competitive pressures and execution risks, have cast a shadow over the company's transformation efforts, even as its stock struggles to recover from significant declines over the past year.
Emerson Electric Co. (NYSE: EMR) is scheduled to release its fiscal fourth-quarter earnings after Tuesday's market close, with investors watching for signs of sustained growth in industrial automation and software.
